ELVN-002
ELVN-002-001
Phase 1 small_molecule active
Quick answer
ELVN-002 for HER2 Mutant Non-small Cell Lung Cancer is a Phase 1 program (small_molecule) at Enliven Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Enliven Therapeutics
- Indication
- HER2 Mutant Non-small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active